Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir-Ruzasvir vs Sofosbuvir-Velpatasvir in Chronic Hepatitis C
NCT07037277Phase 3Active, not recruiting
- Sponsor
- Atea Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of bemnifosbuvir, ruzasvir in hepatitis C (HCV), sponsored by Atea Pharmaceuticals. Started Jun 2025; status: active, not recruiting.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07037277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037277.